CL2021002780A1 - Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismos - Google Patents
Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismosInfo
- Publication number
- CL2021002780A1 CL2021002780A1 CL2021002780A CL2021002780A CL2021002780A1 CL 2021002780 A1 CL2021002780 A1 CL 2021002780A1 CL 2021002780 A CL2021002780 A CL 2021002780A CL 2021002780 A CL2021002780 A CL 2021002780A CL 2021002780 A1 CL2021002780 A1 CL 2021002780A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- well
- methods
- amatoxin
- hematopoietic stem
- Prior art date
Links
- 231100000729 Amatoxin Toxicity 0.000 title abstract 3
- WVHGJJRMKGDTEC-WCIJHFMNSA-N 2-[(1R,4S,8R,10S,13S,16S,27R,34S)-34-[(2S)-butan-2-yl]-8,22-dihydroxy-13-[(2R,3S)-3-hydroxybutan-2-yl]-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide Chemical compound CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N2 WVHGJJRMKGDTEC-WCIJHFMNSA-N 0.000 title abstract 2
- 108010014709 amatoxin Proteins 0.000 title abstract 2
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 2
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- 208000024908 graft versus host disease Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
Se proporcionan amatoxinas, así como conjugados de anticuerpo y fármaco (CAF) que comprenden una amatoxina, así como composiciones y métodos de uso de los mismos. Las composiciones y los métodos proporcionados en el presente documento se pueden utilizar para la terapia del cáncer. También se pueden utilizar para preparar a un paciente para la terapia de trasplante de células madre hematopoyéticas y para mejorar el injerto de trasplantes de células madre hematopoyéticas eliminando de manera selectiva las células madre hematopoyéticas endógenas antes del procedimiento de trasplante. Se proporcionan métodos y composiciones para el tratamiento de diversas enfermedades hematopoyéticas, trastornos metabólicos, cánceres y enfermedades autoinmunitarias, así como para la prevención de la enfermedad del injerto contra el hospedador (EICH).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962838290P | 2019-04-24 | 2019-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002780A1 true CL2021002780A1 (es) | 2022-06-10 |
Family
ID=70617067
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002780A CL2021002780A1 (es) | 2019-04-24 | 2021-10-22 | Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismos |
CL2022003143A CL2022003143A1 (es) | 2019-04-24 | 2022-11-10 | Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismos (divisional solicitud patente 202102780) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022003143A CL2022003143A1 (es) | 2019-04-24 | 2022-11-10 | Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismos (divisional solicitud patente 202102780) |
Country Status (14)
Country | Link |
---|---|
US (2) | US20230135930A1 (es) |
EP (1) | EP3958908A1 (es) |
JP (1) | JP2022530026A (es) |
KR (1) | KR20220003572A (es) |
CN (1) | CN114174317A (es) |
AU (1) | AU2020263959A1 (es) |
BR (1) | BR112021021165A2 (es) |
CA (1) | CA3137373A1 (es) |
CL (2) | CL2021002780A1 (es) |
CO (1) | CO2021014094A2 (es) |
IL (1) | IL287391A (es) |
MX (1) | MX2021012961A (es) |
SG (1) | SG11202110287QA (es) |
WO (1) | WO2020216947A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2978064A1 (en) * | 2015-03-09 | 2016-09-15 | Heidelberg Pharma Gmbh | Amatoxin-antibody conjugates |
AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
JP2021504414A (ja) * | 2017-11-29 | 2021-02-15 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | Cd2+細胞の枯渇のための組成物および方法 |
JP2021530545A (ja) * | 2018-07-23 | 2021-11-11 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 同種異系の細胞療法における抗−cd2抗体薬物コンジュゲート(adc)の使用 |
BR112023018189A2 (pt) * | 2021-03-19 | 2023-10-24 | Heidelberg Pharma Res Gmbh | Conjugados de anticorpos de amatoxina específicos de linfócitos b, composição famacêutica e uso relacionados |
WO2022207825A1 (en) * | 2021-03-31 | 2022-10-06 | Emergence Therapeutics Ag | Anti-nectin-4 antibody exatecan conjugates |
WO2023194539A1 (en) | 2022-04-07 | 2023-10-12 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index of amatoxin-antibody conjugates |
US20240165257A1 (en) | 2022-11-01 | 2024-05-23 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4515894A (en) | 1979-03-20 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing monoclonal antibody to human T cells |
US4363799A (en) | 1979-03-20 | 1982-12-14 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human T cells, and methods for preparing same |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
EP0349578B2 (en) | 1987-03-02 | 1998-10-28 | Enzon Labs Inc. | Organism carrying a Single Chain Antibody Domain at its surface. |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
CA2065299C (en) | 1989-08-09 | 2001-07-24 | Buck A. Rhodes | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
IT1249051B (it) | 1991-02-26 | 1995-02-11 | Italfarmaco Spa | Immunotossina da anticorpi monoclonali anti-cd5 |
AU1771192A (en) | 1991-03-12 | 1992-10-21 | Biogen, Inc. | Monoclonal antibodies recognizing lymphocyte function associated antigen-3 |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US5837491A (en) | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
ES2164699T3 (es) | 1993-03-05 | 2002-03-01 | Univ Catholique Louvain | Anticuerpo lo-cd2a y usos del mismo para inhibir la activacion y la proliferacion de las celulas t. |
US7592006B1 (en) | 1993-03-05 | 2009-09-22 | Université Catholique de Louvain | Composition comprising the LO-CD2a antibody |
US5730979A (en) | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US5951983A (en) | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
US5817311A (en) | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
DE4312916C2 (de) | 1993-04-14 | 1995-03-23 | Fresenius Ag | Arzneimittel zur Behandlung von Immunreaktionen |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5795572A (en) | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
PT749323E (pt) | 1994-03-08 | 2001-05-31 | Dana Farber Cancer Inst Inc | Metodos para modular a anergia das celulas t |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996041608A2 (en) | 1995-06-07 | 1996-12-27 | Thera Pro | Pyrularia thionin containing immunotoxins and immunotoxin-like conjugates |
WO1997023243A1 (en) | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
US6218519B1 (en) | 1996-04-12 | 2001-04-17 | Pro-Neuron, Inc. | Compounds and methods for the selective treatment of cancer and bacterial infections |
EP0957160B1 (en) | 1996-09-03 | 2006-03-22 | Kaneka Corporation | Method for inducing immunosuppressive cells and culturing device to be used therefor |
CA2264227A1 (en) | 1996-09-27 | 1998-04-02 | Raymond A. Firestone | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US6849258B1 (en) | 1997-07-18 | 2005-02-01 | Universite Catholique De Louvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US6358506B1 (en) | 1997-11-05 | 2002-03-19 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
JP2001523645A (ja) | 1997-11-14 | 2001-11-27 | ザ・ゼネラル・ホスピタル・コーポレイション | 血液学的疾患の処置 |
CN1250293C (zh) | 1998-05-22 | 2006-04-12 | 第一制药株式会社 | 药物复合物 |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
AU2980900A (en) | 1999-02-04 | 2000-08-25 | General Hospital Corporation, The | Methods for human allografting |
US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
US6541611B1 (en) | 1999-06-18 | 2003-04-01 | Universite Catholique De Louvain | LO-CD2b antibody |
US20040052793A1 (en) | 2001-02-22 | 2004-03-18 | Carter Paul J. | Caspase activivated prodrugs therapy |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
US20050069538A1 (en) | 2003-09-18 | 2005-03-31 | Gregorio Aversa | Therapeutic binding molecules |
AU2002322478A1 (en) | 2001-03-02 | 2002-12-16 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
US7265212B2 (en) | 2001-12-03 | 2007-09-04 | Amgen Fremont Inc. | Anti-CD45RB antibodies |
US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
US6887673B2 (en) | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
EP1575514A2 (en) | 2002-07-31 | 2005-09-21 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
WO2004022097A1 (en) | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
KR100694508B1 (ko) | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Hbbk4항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
KR100745488B1 (ko) | 2006-07-04 | 2007-08-02 | 학교법인 울산공업학원 | 항-4-1bb 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물 |
ITBO20070242A1 (it) | 2007-04-03 | 2008-10-04 | Gsg Int Spa | Profilato per serramenti scorrevoli, metodo per la realizzazione del profilato, e serramento ottenuto con il profilato stesso. |
KR20080107050A (ko) | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-cd137 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
US20110229460A1 (en) | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
BRPI0917148A2 (pt) | 2008-08-29 | 2015-12-01 | Symphogen As | anticorpos anti-cd5 |
WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
HUE050296T2 (hu) | 2009-04-08 | 2020-11-30 | Faulstich Heinz Dr | Amatoxinnel fegyveres terápiás sejtfelszíni kötõ komponensek, amelyeket daganatterápiára terveztek |
WO2010132389A2 (en) | 2009-05-14 | 2010-11-18 | University Of Maryland, Baltimore | Methods for treating cancers and diseases associated with 4-1bb (cd137) expression |
DK2430051T3 (en) | 2009-05-14 | 2016-07-04 | Inst Nat De La Santé Et De La Rech Medicale | Compositions containing antibodies for the treatment of CD5 + HLA-DR + B- or T-cell-related diseases |
WO2011031063A2 (ko) | 2009-09-09 | 2011-03-17 | 울산대학교 산학협력단 | 항 4-1bb 항체를 포함하는 대사성 질환의 예방 또는 치료용 조성물 |
WO2011071871A1 (en) | 2009-12-07 | 2011-06-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for enhancing anti-tumor antibody therapy |
KR20110085038A (ko) | 2010-01-19 | 2011-07-27 | 울산대학교 산학협력단 | 항 cd137-항체 및 독소 결합물을 이용한 cd137 양성세포의 제거방법 |
EP2614083A2 (en) | 2010-09-08 | 2013-07-17 | Yeda Research and Development Co. Ltd | An immunosuppressive drug combination for a stable and long term engraftment |
EP2614082B1 (en) | 2010-09-09 | 2018-10-03 | Pfizer Inc | 4-1bb binding molecules |
EP2436398B1 (en) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
WO2012145183A2 (en) | 2011-04-19 | 2012-10-26 | Pfizer Inc. | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
SG11201403456UA (en) | 2011-12-22 | 2014-07-30 | Yeda Res & Dev | A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion |
US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
WO2014043403A1 (en) | 2012-09-12 | 2014-03-20 | Agensys, Inc. | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
US9498543B2 (en) * | 2013-03-15 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
WO2015095755A1 (en) | 2013-12-19 | 2015-06-25 | Seattle Genetics, Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
EP3102604B1 (en) | 2014-02-04 | 2020-01-15 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
EP3145956A1 (en) | 2014-05-21 | 2017-03-29 | Pfizer Inc. | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer |
WO2015188047A1 (en) | 2014-06-06 | 2015-12-10 | University Of Maryland, Baltimore | ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY |
JP6692343B2 (ja) | 2014-08-01 | 2020-05-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 薬物としての使用のための抗cd45rc抗体 |
WO2016029073A2 (en) | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
JP6733993B2 (ja) | 2014-10-03 | 2020-08-05 | シンアフィックス ビー.ブイ. | スルファミドリンカー、スルファミドリンカーのコンジュゲート、及び調製の方法 |
EP3215519A1 (en) | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
EP3026060A1 (en) | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for CD45R0 |
ES2922398T3 (es) | 2015-01-08 | 2022-09-14 | BioNTech SE | Agentes agonistas de unión al receptor de TNF |
AU2016219772A1 (en) | 2015-02-22 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD137 |
CA2978064A1 (en) * | 2015-03-09 | 2016-09-15 | Heidelberg Pharma Gmbh | Amatoxin-antibody conjugates |
WO2016172606A1 (en) | 2015-04-23 | 2016-10-27 | Baylor College Of Medicine | Cd5 chimeric antigen receptor for adoptive t cell therapy |
WO2016185016A1 (en) | 2015-05-21 | 2016-11-24 | Alligator Bioscience Ab | Novel polypeptides |
CN113214398B (zh) | 2015-09-22 | 2022-04-08 | 苏州丁孚靶点生物技术有限公司 | 抗人cd137的完全人抗体及其应用 |
GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
US20170129128A1 (en) | 2015-11-05 | 2017-05-11 | Black & Decker Inc. | Saw |
EP3394770A4 (en) | 2015-12-22 | 2019-05-01 | 3M Innovative Properties Company | HEALTH MANAGEMENT SYSTEM WITH MULTIDIMENSIONAL PERFORMANCE REPRESENTATION |
KR20210013777A (ko) | 2016-01-25 | 2021-02-05 | 화이자 인코포레이티드 | 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합 |
EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
EP3426305A4 (en) | 2016-03-07 | 2020-01-08 | Actinium Pharmaceuticals, Inc. | STABILIZED RADIOACTIVELY MARKED ANTI-CD45 IMMUNOGLOBULIN COMPOSITIONS |
US11104739B2 (en) | 2016-04-14 | 2021-08-31 | Bristol-Myers Squibb Company | Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody |
EP3445401A4 (en) | 2016-04-20 | 2019-11-20 | Hangzhou DAC Biotech Co, Ltd | DERIVATIVES OF AMANITA TOXINES AND THEIR CONJUGATION TO A CELL BINDING MOLECULE |
CN109195631B (zh) * | 2016-05-31 | 2022-11-29 | 索伦托药业有限公司 | 具有鹅膏毒肽的衍生物作为药物的抗体药物缀合物 |
CA3030634A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
WO2018098370A1 (en) | 2016-11-23 | 2018-05-31 | Immunoah Therapeutics, Inc. | 4-1bb binding proteins and uses thereof |
BR112019012937A2 (pt) | 2016-12-23 | 2019-12-10 | Heidelberg Pharma Res Gmbh | novo conjugado de amanitina |
KR102427192B1 (ko) | 2017-01-06 | 2022-07-29 | 주식회사 유틸렉스 | 항-인간 4-1bb 항체 및 그의 용도 |
MX2019008205A (es) * | 2017-01-20 | 2020-01-23 | Magenta Therapeutics Inc | Composiciones y metodos para el agotamiento de células cd137+. |
IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific molecules that bind CD137 and cancer antigens and their uses |
BR112019017241A2 (pt) | 2017-04-13 | 2020-04-14 | Agenus Inc | anticorpos anti-cd137 e métodos de uso dos mesmos |
EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
MA49749A (fr) | 2017-08-01 | 2021-03-24 | Lilly Co Eli | Anticorps anti-cd137 |
AU2018314668B2 (en) * | 2017-08-07 | 2022-06-02 | Heidelberg Pharma Research Gmbh | Novel method for synthesizing amanitins |
CN111511762A (zh) | 2017-08-21 | 2020-08-07 | 天演药业公司 | 抗cd137分子及其用途 |
CN111989122A (zh) | 2018-04-13 | 2020-11-24 | 海德堡医药研究有限责任公司 | 用于治疗实体瘤的靶向鹅膏毒素缀合物 |
CA3104800A1 (en) | 2018-07-31 | 2020-02-06 | Heidelberg Pharma Research Gmbh | Humanized antibodies against psma |
-
2020
- 2020-04-24 JP JP2021562940A patent/JP2022530026A/ja active Pending
- 2020-04-24 CA CA3137373A patent/CA3137373A1/en active Pending
- 2020-04-24 MX MX2021012961A patent/MX2021012961A/es unknown
- 2020-04-24 AU AU2020263959A patent/AU2020263959A1/en active Pending
- 2020-04-24 KR KR1020217038138A patent/KR20220003572A/ko active Search and Examination
- 2020-04-24 WO PCT/EP2020/061555 patent/WO2020216947A1/en unknown
- 2020-04-24 US US17/605,766 patent/US20230135930A1/en active Pending
- 2020-04-24 SG SG11202110287QA patent/SG11202110287QA/en unknown
- 2020-04-24 BR BR112021021165A patent/BR112021021165A2/pt unknown
- 2020-04-24 US US16/858,509 patent/US20200407440A1/en not_active Abandoned
- 2020-04-24 CN CN202080046209.5A patent/CN114174317A/zh active Pending
- 2020-04-24 EP EP20724752.9A patent/EP3958908A1/en active Pending
-
2021
- 2021-10-19 IL IL287391A patent/IL287391A/en unknown
- 2021-10-22 CO CONC2021/0014094A patent/CO2021014094A2/es unknown
- 2021-10-22 CL CL2021002780A patent/CL2021002780A1/es unknown
-
2022
- 2022-11-10 CL CL2022003143A patent/CL2022003143A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021021165A2 (pt) | 2022-01-04 |
CO2021014094A2 (es) | 2022-01-28 |
KR20220003572A (ko) | 2022-01-10 |
US20200407440A1 (en) | 2020-12-31 |
CL2022003143A1 (es) | 2023-04-21 |
AU2020263959A1 (en) | 2021-11-25 |
WO2020216947A1 (en) | 2020-10-29 |
JP2022530026A (ja) | 2022-06-27 |
EP3958908A1 (en) | 2022-03-02 |
MX2021012961A (es) | 2021-11-25 |
CN114174317A (zh) | 2022-03-11 |
SG11202110287QA (en) | 2021-10-28 |
US20230135930A1 (en) | 2023-05-04 |
CA3137373A1 (en) | 2020-10-29 |
IL287391A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002780A1 (es) | Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismos | |
CO2020004906A2 (es) | Composiciones y métodos para la eliminación de células cd117+ | |
HN2011001195A (es) | Compuestos que expanden las celulas madre hematopoieticas | |
CO2021006259A2 (es) | Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos | |
GT200600297A (es) | Nuevos anticuerpos anti-madcam | |
WO2019084057A3 (en) | Compositions and methods for the depletion of cd117+ cells | |
AR105808A1 (es) | Compuestos de amida para el tratamiento de trastornos médicos | |
CO6382119A2 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
DOP2012000131A (es) | Antagonistas de espiro-oxindol de mdm2 | |
CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
CO2020006855A2 (es) | Composiciones y métodos para el agotamiento de células cd2+ | |
MX2021002932A (es) | Metodo para obtener una poblacion enriquecida de celulas madre mesenquimales funcionales, celulas obtenidas de la misma y composiciones que las comprenden. | |
MX2021004579A (es) | Métodos para trasplante de células madre hematopoyéticas alogénicas. | |
CR20160254A (es) | Composiciones y métodos útiles en el tratamiento de síntomas del tracto urinario inferior, hiperplasia prostática benigna, disfunción eréctil. | |
CL2020003319A1 (es) | Receptores del factor de crecimiento quiméricos | |
CO2020007275A2 (es) | Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas | |
CO2020006865A2 (es) | Composiciones y métodos para el agotamiento de células cd5+ | |
AR120057A1 (es) | Composiciones neoantigénicas y usos de estas | |
CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. | |
AR047005A1 (es) | Cuerpos de inclusion que transportan glicerol-fosfato aceptables para uso farmaceutico | |
ATE556134T1 (de) | Mesenchymstammzellen und verwendungendafür | |
CL2021002735A1 (es) | Anticuerpos anti-pd-l1 modificados y métodos y usos para el tratamiento de una enfermedad neurodegenerativa | |
WO2020219778A3 (en) | Anti-cd117 antibody-drug conjugates and uses thereof | |
ECSP078006A (es) | Fracción activa de un extracto de látex de las plantas de la familia de las euphorbiaceae en solvente polar |